Is STAA a Good Stock to Buy? The Bull and Bear Case (2026)
Last updated November 2026
Short answer
Both cases are real, which is why the question is contested. The bull case for STAAR Surgical (STAA) rests on China demand and pricing: China produced ~$52.3 million of sales in the second quarter of 2026 and ~$39.3 million in the third, against ~$44.1 million from every other market combined in the third quarter. The bear case rests on close to half of revenue flows through one Chinese distributor network, and 2025 showed how quickly that can reverse: sales fell 23.7% while channel inventory was worked down, and an unclear inventory picture can return. Analysts covering it publish targets from $19.00 to $37.00 against a $24.22 share price on November 20, 2026, so even the professionals disagree by 63% of their own average. We do not give a verdict. Each case is set out below at full strength, so you can decide which set of assumptions you actually believe. Walnut is not an investment adviser.
STAA key stats
At $24.22 on November 20, 2026, STAAR Surgical (STAA) has a market cap of $1.2B and a P/E of 2422.0 on trailing earnings (21.4 on forward earnings).
- Market cap
- $1.2B
- P/E (trailing)
- 2422.0
- P/E (forward)
- 21.4
- EPS (trailing 12 months)
- $0.01
- Price to book
- 3.2
- Beta
- 1.20
Market cap, P/E and yield are measured at the $24.22 price on November 20, 2026, from Yahoo Finance figures pulled in November 2026. Earnings date from Yahoo Finance. Walnut is informational, not investment advice.
What's new with STAAR Surgical (STAA)?
The last two weeks for STAAR Surgical, as of November 22, 2026: the price move, the next earnings date, and what analysts changed.
- STAA closed at $24.22 on November 20, 2026, down 8.2% over the past five trading days (from $26.39).
Prices are daily closes from Yahoo Finance. Analyst actions come from Yahoo Finance as of November 2026. Walnut is informational, not investment advice.
STAAR Surgical, based in Lake Forest, California, makes implantable lenses for vision correction. Its main product is the EVO Implantable Collamer Lens (ICL), a soft lens that a surgeon slips behind the iris and in front of the eye's natural lens, correcting myopia, with or without astigmatism, without removing corneal tissue the way LASIK or SMILE do. The lens can be taken out later. It is sold in more than 75 countries, gained U.S. FDA approval in its EVO form in 2022, and is manufactured in Monrovia, California and in Switzerland. Nearly all revenue comes from the ICL family, including the newer EVO+ with a larger optic and toric versions for astigmatism. The last two years have been unusually eventful. Net sales fell 23.7% in 2025 to ~$239.4 million, with a ~$80.4 million net loss, as Chinese distributors worked through excess inventory. Alcon agreed in August 2025 to buy the company for $28 a share, raised the price to $30.75 in December after a go-shop period, and still lost the vote: on January 6, 2026, about 27.3 million shares voted against and 14.9 million for. The agreement was terminated with no fee owed by either side. A cooperation agreement with Broadwood Partners, the largest holder, followed on January 14, bringing three new directors and the exit of CEO Stephen Farrell. Warren Foust, previously president and chief operating officer, became permanent CEO on August 4, 2026. The business has since recovered. Sales for the first nine months of 2026 reached a record ~$270.5 million with ~$18.8 million of net income. The third quarter showed ~$83.4 million of sales, down 12% only because the prior year included ~$25.9 million of deferred China shipments, and gross margin dropped to 70.9% on tariffs. Cash and investments stand at ~$206.4 million with no debt, and the board approved a $50 million buyback in September. Third-quarter adjusted EPS of $0.19 came in a cent under the $0.20 consensus in Yahoo Finance data. At ~$24.12 on November 20, 2026 the stock trades about 22% below the rejected $30.75 offer, so holders are now carrying China, tariff and competition risk directly. The nine analysts in Yahoo Finance's current count rate it a Buy on average, with a mean target of about $28.56.
The bull case: what would have to be true for $37.00
The most optimistic published target on STAA is $37.00, +52.8% from the $24.22 share price on November 20, 2026. Getting there needs the following to work close to its best case, not merely to avoid going wrong.
1. China demand and pricing
China produced ~$52.3 million of sales in the second quarter of 2026 and ~$39.3 million in the third, against ~$44.1 million from every other market combined in the third quarter. Management says distributor unit shipments rose 12.4% over the first nine months and that its share of the Chinese refractive surgery market grew as patients chose the ICL over laser procedures. Average selling prices rose as EVO+ and toric lenses took a bigger part of the mix, and third-quarter growth in China came entirely from price because the company could not make enough lenses to meet demand. Distributor inventory ended the quarter below the six-month target, so supply, not demand, limited the quarter.
2. Growth outside China
Sales outside China rose 13% in the third quarter to ~$44.1 million. EMEA grew 31% (51% excluding the Middle East) and the Americas grew 14%, while Asia-Pacific excluding China rose only 4% with declines in Japan and South Korea. The U.S. is still small, at ~$6.5 million in the third quarter, four years after the EVO lens won FDA approval, so U.S. surgeon adoption is still at an early stage. The 2025 numbers set the floor: sales excluding China grew 6.6% that year to ~$161.7 million. A steadier non-China base would make the company less exposed to one distributor network and one regulator.
3. Margin repair after the tariff hit
Gross margin slipped to 70.9% in the third quarter of 2026 from 82.2% a year earlier (75.5% excluding the deferred China revenue), largely because U.S.-made lenses shipped to China carried tariffs. By the end of the quarter all China-bound manufacturing had moved to Switzerland, and management expects fourth-quarter margins above the third, with unit costs improving further in 2027. Operating expenses fell to ~$174.2 million over nine months from ~$207.6 million, and the company says it is on track for a $225 million annual target. Adjusted EBITDA was ~$58.8 million over the same nine months, against breakeven in the fourth quarter of 2025.
4. Capital return and governance under new leadership
STAAR has ~$206.4 million in cash and investments, no debt, and a $50 million share repurchase program authorized in September 2026, which management tied to its view that the shares are undervalued. Since the Broadwood cooperation agreement the board has seven seats, three of them filled by people linked to Broadwood and Yunqi Capital, the two holders that led opposition to the Alcon deal. Foust has set three company goals: revenue growth, profit expansion and faster product development. Ying Chen was elevated to president of STAAR Surgical China. How the new board allocates the cash pile, between buybacks, manufacturing capacity and research, will shape per-share results over the next few years.
The bear case: what would have to be true for $19.00
The most pessimistic published target is $19.00, -21.6% from the current price. It is neither a floor nor a forecast; it is roughly what one analyst thinks STAAR Surgical is worth if the risks below bite instead of the drivers above.
Close to half of revenue flows through one Chinese distributor network, and 2025 showed how quickly that can reverse: sales fell 23.7% while channel inventory was worked down, and an unclear inventory picture can return. Chinese competition is now real. Eyebright Medical's Loong Crystal PR phakic lens was approved by China's NMPA in January 2025, and a small Fudan University study found similar efficacy and safety against the EVO ICL in paired eyes. Hospital procurement policy in China, including volume-based purchasing that has squeezed prices for cataract lenses, could reach phakic lenses. Tariffs already cut third-quarter gross margin by several points, and U.S.-origin product sold into China is still subject to them. Japan and South Korea are declining. The ICL is effectively the whole company, so a safety signal, a recall or a manufacturing problem at either plant would hit every line of the income statement. Finally, the share price no longer has a takeover floor. Holders who rejected $30.75 are relying on the standalone plan, and the stock has traded between ~$15.59 and ~$35.87 over the past 52 weeks.
The bear case deserves the same attention as the bull case, and usually gets less. If you are holding STAA already, these risks exist either way; what to check is whether any of them has moved from possible to actually happening in the reported numbers.
Where analysts land on STAA
9 analysts cover STAA, with an average target of $28.56 (+17.9% against $24.22) and a split of 4 buy, 6 hold, 1 sell. Bear in mind sell-side ratings skew positive across the whole market, so that split is not a balanced vote. The full target table, the recent rating actions by firm, and how the consensus has shifted are on the STAA forecast and price target page.
How is STAA valued?
Market cap, P/E and dividend yield at today's price are in the STAA key stats above. The business figures below come from STAAR Surgical's reported results as of November 2026 and change when it next reports.
- Revenue (TTM through Q3 2026): ~$328M
- Net income (TTM through Q3 2026): ~breakeven (~$18.8M for 9M 2026)
- Adjusted EBITDA (9M 2026): ~$58.8M
- Gross margin (Q3 2026): ~70.9% (82.2% a year earlier)
- Cash and investments (Oct 2, 2026): ~$206.4M, no debt
As of November 2026: Trailing revenue of about $328 million combines the weak fourth quarter of 2025 (~$57.8 million and an ~$18.3 million loss) with three strong 2026 quarters, so the trailing GAAP profit of roughly zero understates the current run rate. Taking off the cash, enterprise value is about $1.0 billion, around 3.1 times trailing sales and about 13 times nine-month adjusted EBITDA annualized; the forward P/E is about 21 on 2027 EPS estimates near $1.13. The shares sit about 22% below Alcon's rejected $30.75 offer and under the ~$28.56 mean analyst target, with a Buy average from nine analysts.
How do you decide if STAA is a buy?
Whether STAA is a buy is easier to judge through four narrower questions:
- Thesis: do you believe the bull case above, and is it still true today?
- Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
- Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
- Overlap: check whether you already hold STAA indirectly through an index or sector ETF before adding more.
What would change your mind on STAA
Write the tripwires down before you need them. Deciding what would falsify your view is far harder once a position is moving against you.
- Bull case breaks if: China demand and pricing stalls in the reported numbers. A shift in the narrative around them is not enough on its own.
- Bear case breaks if: close to half of revenue flows through one Chinese distributor network, and 2025 showed how quickly that can reverse: sales fell 23.7% while channel inventory was worked down, and an unclear inventory picture can return fails to materialise over several reporting periods while the drivers keep compounding.
- Neither matters if: the position has grown large enough that being wrong would damage the whole portfolio. Sizing overrides the argument.
For the full picture, see the STAA stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about STAA against your real portfolio and see your actual exposure before deciding.
Your questions about STAAR Surgical
Ask Walnut's AI anything about STAA and see how it fits what you own.
FAQ
Is STAA a good stock to buy right now?
+
That depends on which case you find more convincing, and both are on this page. The bull case rests on China demand and pricing, with revenue (ttm through q3 2026) at ~$328M. The bear case rests on close to half of revenue flows through one Chinese distributor network, and 2025 showed how quickly that can reverse: sales fell 23.7% while channel inventory was worked down, and an unclear inventory picture can return. Analysts covering it are spread from $19.00 to $37.00, a spread wide enough to show the question is contested. If you believe the thesis, the questions that matter next are sizing and overlap; timing comes after. Walnut is not an investment adviser and this is not a recommendation.
Should I sell STAA?
+
Nobody can answer that for you, and a more useful version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. Close to half of revenue flows through one Chinese distributor network, and 2025 showed how quickly that can reverse: sales fell 23.7% while channel inventory was worked down, and an unclear inventory picture can return. If that risk is what you were worried about and it is now playing out, take it seriously. If the price simply fell while the thesis held, the situation is different. The most pessimistic published target is $19.00, -21.6% from the $24.22 price, which is one analyst's downside case. It is not a floor. Walnut is not an investment adviser.
What is the bull case for STAA?
+
China demand and pricing. China produced ~$52.3 million of sales in the second quarter of 2026 and ~$39.3 million in the third, against ~$44.1 million from every other market combined in the third quarter. The most optimistic analyst target on STAA is $37.00, +52.8% from the $24.22 price. That figure is only reachable if this thesis works close to its best case.
What is the bear case for STAA?
+
Close to half of revenue flows through one Chinese distributor network, and 2025 showed how quickly that can reverse: sales fell 23.7% while channel inventory was worked down, and an unclear inventory picture can return. Chinese competition is now real. Eyebright Medical's Loong Crystal PR phakic lens was approved by China's NMPA in January 2025, and a small Fudan University study found similar efficacy and safety against the EVO ICL in paired eyes. Hospital procurement policy in China, including volume-based purchasing that has squeezed prices for cataract lenses, could reach phakic lenses. Tariffs already cut third-quarter gross margin by several points, and U.S.-origin product sold into China is still subject to them. Japan and South Korea are declining. The ICL is effectively the whole company, so a safety signal, a recall or a manufacturing problem at either plant would hit every line of the income statement. Finally, the share price no longer has a takeover floor. Holders who rejected $30.75 are relying on the standalone plan, and the stock has traded between ~$15.59 and ~$35.87 over the past 52 weeks. The most pessimistic published target is $19.00, -21.6% from the current price, which is roughly what one analyst thinks the stock is worth if these risks bite and the drivers do not.
What does STAAR Surgical do?
+
Maker of implantable Collamer lenses (EVO ICL) for vision correction; the Alcon buyout was voted down in January 2026.
What would have to change for STAA to stop being worth holding?
+
Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (China demand and pricing) stalling in the reported numbers (a change in the narrative alone does not count), the risk above (close to half of revenue flows through one Chinese distributor network, and 2025 showed how quickly that can reverse: sales fell 23.7% while channel inventory was worked down, and an unclear inventory picture can return) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.
How do you invest in STAAR Surgical stock?
+
STAAR Surgical trades on the Nasdaq under the ticker STAA, so any brokerage account that offers U.S. stocks can hold it, including apps that sell fractional shares. Shares closed near ~$24.12 on November 20, 2026, a market value of about ~$1.21 billion across roughly 50.5 million shares. The company pays no dividend; it returns cash through a $50 million buyback authorized in September 2026. Because one product line and one country (China) drive most of the results, many investors size STAA as a smaller satellite holding inside a broader healthcare or medical device allocation. Medical device ETFs that hold small caps may include it at low weights, but the stock itself is the only way to get concentrated exposure to the ICL. Walnut can show how a position like this sits beside the rest of a portfolio; it is not an investment adviser and does not make buy or sell calls.
What happened to the Alcon acquisition of STAAR Surgical?
+
It failed. Alcon agreed on August 4, 2025 to buy STAAR for $28 a share in cash. Broadwood Partners, the largest holder, and Yunqi Capital campaigned against the price. After a go-shop period produced no rival bid, Alcon raised the offer to $30.75 in December 2025, about $1.6 billion of equity value. At the special meeting on January 6, 2026, roughly 27.3 million shares voted against and 14.9 million for, so the merger was not approved. STAAR's 8-K filed that day (Items 1.02 and 5.07) confirms the agreement was terminated effective January 6, with no termination fee owed by either company. STAAR has traded as a standalone public company since, and a January 14 cooperation agreement gave Broadwood-linked nominees board seats.
What is the EVO ICL and how does it differ from LASIK?
+
The EVO Implantable Collamer Lens is a thin, flexible lens made of Collamer, a collagen copolymer, that a surgeon places behind the iris and in front of the eye's natural lens through a small incision. It corrects nearsightedness and, in toric versions, astigmatism. LASIK, PRK and SMILE reshape the cornea by removing tissue with a laser, which cannot be undone. The ICL leaves the cornea intact and can be removed or exchanged, which makes it suited to patients with high myopia or thin corneas who are poor laser candidates. The EVO design includes a central port that removed the need for a separate laser hole in the iris used with earlier models. Per eye it usually costs more than laser surgery, so its growth depends on surgeons and patients deciding the trade is worth it.
Walnut is informational, not investment advice, and gives no verdict on STAA. Analyst targets referenced here come from a November 2026 pull of published third-party research and change constantly. The share price is the last one Yahoo Finance reported on November 20, 2026. Verify current figures with your broker before acting on them.